Increasing brain acetylcholine levels by another acetylcholinesterase inhibitor, physostigmine, triggers anxiety, and depression in control human subjects and in patients with mood disorders (Janowsky and Overstreet 1990; Risch et al. 1980), whereas blocking acetylcholinesterase activity induces depression/anxiety‐like behavior and social stress in rodents as well, and these effects can be reversed by blocking cholinergic receptors (Mineur et al. 2013). Here, ACHE is linked to depressive symptom measurement.